{"filing":{"accession_number":"0001437749-26-027311","cik":"0001427925","ticker":"TLPH","company_name":"TALPHERA, INC.","form":"8-K","filing_date":"2026-08-12","report_date":"2026-08-12","primary_document":"acrx20260811_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1427925/000143774926027311/acrx20260811_8k.htm"},"events":[{"id":27184,"run_id":24757,"accession_number":"0001437749-26-027311","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"This is a standard quarterly earnings release for Q2 2026 disclosing financial results (net loss of $4.3 million, cash position of $17.1 million) and operational updates on the NEPHRO CRRT clinical trial (75% enrollment) and regulatory developments (KDIGO guideline inclusion). The filing explicitly states the press release is furnished as Exhibit 99.1 under Item 2.02, which is the standard Item for earnings releases. Material to investors assessing the company's financial condition and clinical progress.","company_name":"TALPHERA, INC.","ticker":"TLPH","filing_date":"2026-08-12","form":"8-K","submitted_at":null,"items":[{"id":28606,"accession_number":"0001437749-26-027311","item_number":"2.02","item_title":"Results of Operations and Financial Condition","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"This is a standard quarterly earnings release for Q2 2026 disclosing financial results (net loss of $4.3 million, cash position of $17.1 million) and operational updates on the NEPHRO CRRT clinical trial (75% enrollment) and regulatory developments (KDIGO guideline inclusion). The filing explicitly states the press release is furnished as Exhibit 99.1 under Item 2.02, which is the standard Item for earnings releases. Material to investors assessing the company's financial condition and clinical progress.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-12T20:12:52.498639+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":28606,"accession_number":"0001437749-26-027311","item_number":"2.02","item_title":"Results of Operations and Financial Condition","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"This is a standard quarterly earnings release for Q2 2026 disclosing financial results (net loss of $4.3 million, cash position of $17.1 million) and operational updates on the NEPHRO CRRT clinical trial (75% enrollment) and regulatory developments (KDIGO guideline inclusion). The filing explicitly states the press release is furnished as Exhibit 99.1 under Item 2.02, which is the standard Item for earnings releases. Material to investors assessing the company's financial condition and clinical progress.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-12T20:12:52.498639+00:00","company_name":"TALPHERA, INC.","ticker":"TLPH","filing_date":"2026-08-12"}]}